480 Arsenal Street, Suite 110Watertown, MA 02472
Guy Macdonald, BSc
President & CEO
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals (NASDAQ: TTPH) is a publicly traded clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.
Doug Cole is on the Board of Directors.